{"title":"Methylation of DPP9 regulates immune surveillance in non-small cell lung cancer by promoting macrophage ferroptosis via WWP2 ubiquitination.","authors":"Haiyan Lin, Ying Chen, Nana Wang, Shan Zhang","doi":"10.62347/XZWR5194","DOIUrl":null,"url":null,"abstract":"<p><p>Lung cancer is one of the most common malignancies worldwide, with approximately 2.2 million new cases diagnosed annually. About 75% of patients die within five years of diagnosis. Non-small cell lung cancer (NSCLC) is the predominant histological subtype. In the present study, we aimed to comprehensively elucidate the effects of dipeptidyl peptidase 9 (DPP9) in model of NSCLC. DPP9 mRNA expression and protein expression were up-regulation in patients with NSCLC. Then, Sh-DPP9 reduced cancer growth in mice model of NSCLC. N6-methyladenosine (m6A) increased DPP9 RNA stability of macrophage in NSCLC. DPP9 reduced immune surveillance and promoted Macrophage ferroptosis in vitro model. Meanwhile, si-DPP9 increased immune surveillance and reduced Macrophage ferroptosis in vitro model. DPP9 increased reactive oxygen species (ROS) ROS-mitochondrial oxidation and mitochondrial damage in Macrophage of vitro model. DPP9 reduced activating transcription factor 4 (ATF4) protein expression to promote WW domain-containing E3 ubiquitin protein ligase 2 (WWP2) ubiquitination in Macrophage. ATF4 inhibitor or WWP2 inhibitor reduced the effects of si-DPP9 in ferroptosis of macrophage in model of NSCLC. In conclusion, DPP9 up-regulation promotes WWP2 ubiquitination, thereby inhibiting the WWP2/ATF4 signaling pathway and enhancing macrophage ferroptosis, which leads to reduced immune surveillance and promotes tumor progression in NSCLC.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"16 7","pages":"3025-3048"},"PeriodicalIF":3.1000,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13468242/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/XZWR5194","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Lung cancer is one of the most common malignancies worldwide, with approximately 2.2 million new cases diagnosed annually. About 75% of patients die within five years of diagnosis. Non-small cell lung cancer (NSCLC) is the predominant histological subtype. In the present study, we aimed to comprehensively elucidate the effects of dipeptidyl peptidase 9 (DPP9) in model of NSCLC. DPP9 mRNA expression and protein expression were up-regulation in patients with NSCLC. Then, Sh-DPP9 reduced cancer growth in mice model of NSCLC. N6-methyladenosine (m6A) increased DPP9 RNA stability of macrophage in NSCLC. DPP9 reduced immune surveillance and promoted Macrophage ferroptosis in vitro model. Meanwhile, si-DPP9 increased immune surveillance and reduced Macrophage ferroptosis in vitro model. DPP9 increased reactive oxygen species (ROS) ROS-mitochondrial oxidation and mitochondrial damage in Macrophage of vitro model. DPP9 reduced activating transcription factor 4 (ATF4) protein expression to promote WW domain-containing E3 ubiquitin protein ligase 2 (WWP2) ubiquitination in Macrophage. ATF4 inhibitor or WWP2 inhibitor reduced the effects of si-DPP9 in ferroptosis of macrophage in model of NSCLC. In conclusion, DPP9 up-regulation promotes WWP2 ubiquitination, thereby inhibiting the WWP2/ATF4 signaling pathway and enhancing macrophage ferroptosis, which leads to reduced immune surveillance and promotes tumor progression in NSCLC.
期刊介绍:
The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.